Pharming Group NV Asset Resilience Ratio

Latest as of September 2025: 7.13%

Pharming Group NV asset resilience ratio. Pharming Group NV (PHARM) has an Asset Resilience Ratio of 7.13% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHARM defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€33.80 Million

≈ $39.51 Million USD Cash + Short-term Investments

Total Assets

€473.79 Million

≈ $553.90 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Pharming Group NV (2005–2024)

Asset resilience ratio of Pharming Group NV from 2005 to 2024. This chart shows how Pharming Group NV's Asset Resilience Ratio has changed over time. Read Pharming Group NV total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Pharming Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PHARM asset base.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€33.80 Million	7.13%
Total Liquid Assets	€33.80 Million	7.13%

Asset Resilience Insights

Limited Liquidity: Pharming Group NV maintains only 7.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pharming Group NV Industry Peers by Asset Resilience Ratio

Compare Pharming Group NV's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	15.21%
Abivax SA PA:ABVX	Biotechnology	2.58%
Tubize-Fin BR:TUB	Biotechnology	2.50%
BB Biotech AG SW:BION	Biotechnology	92.97%
Sinocelltech Group Ltd SHG:688520	Biotechnology	5.27%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	1.75%
Mineralys Therapeutics, Inc. Common Stock NASDAQ:MLYS	Biotechnology	78.33%
GH Research PLC NASDAQ:GHRS	Biotechnology	4.73%

Pharming Group NV Asset Resilience Ratio by Year (2005–2024)

Pharming Group NV asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Pharming Group NV.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	28.18%	€109.03 Million ≈ $127.47 Million	€386.88 Million ≈ $452.30 Million	-4.03pp
2023-12-31	32.21%	€137.31 Million ≈ $160.53 Million	€426.34 Million ≈ $498.44 Million	--
2022-12-31	0.00%	€0.00 ≈ $0.00	€425.80 Million ≈ $497.80 Million	--
2019-12-31	-0.26%	€-661.91K ≈ $-773.84K	€255.63 Million ≈ $298.86 Million	-5.84pp
2008-12-31	5.59%	€5.22 Million ≈ $6.10 Million	€93.40 Million ≈ $109.20 Million	-11.30pp
2005-12-31	16.88%	€6.92 Million ≈ $8.09 Million	€40.96 Million ≈ $47.89 Million	--

pp = percentage points

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$902.47 Million

€771.93 Million EUR

Market Cap Rank

#9086 Global

#54 in Netherlands

Share Price

€1.11

Change (1 day)

-0.05%

52-Week Range

€0.83 - €1.78

All Time High

€1.78